HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Screen & Chart at the same time

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Rani Therapeutics, LLC

Contributing Author

Recent Articles by Rani Therapeutics, LLC

May-15
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition RANI GlobeNewswire
May-12
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference RANI GlobeNewswire
Apr-09
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy RANI -6.15% GlobeNewswire
Mar-26
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update RANI -24.94% RANI -5.26% GlobeNewswire
Mar-25
Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization RANI +7.55% GlobeNewswire
Mar-19
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results RANI GlobeNewswire
Jan-28
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer RANI GlobeNewswire
Jan-08
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen RANI GlobeNewswire
Nov-24
Rani Therapeutics to Participate in the Evercore Healthcare Conference RANI GlobeNewswire
Nov-06
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update RANI -11.01% RANI -9.20% GlobeNewswire
Oct-30
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill Capsule at ObesityWeek 2025 RANI -12.65% GlobeNewswire
Oct-23
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors RANI -13.46% RANI -12.92% GlobeNewswire
Oct-23
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules RANI -13.46% RANI -12.92% GlobeNewswire
Oct-17
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules RANI +248.27% GlobeNewswire
Oct-17
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing RANI +248.27% GlobeNewswire
Aug-07
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update RANI GlobeNewswire
Jul-15
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering RANI -38.92% GlobeNewswire
Jul-14
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery RANI +8.45% GlobeNewswire
May-19
Rani Therapeutics Announces Research Agreement with Chugai RANI +9.27% GlobeNewswire
May-13
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update RANI -21.42% RANI +15.59% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)